NCT01753791View on ClinicalTrials.gov

Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Healthy
Interventions
DRUG

80 mg PF-06473871

80 mg of PF-06473871 or placebo

DRUG

160 mg PF-06473871

160 mg of PF-06473871 or placebo

DRUG

320 mg PF-06473871

320 mg of PF-06473871 or placebo

DRUG

480 mg PF-06473871

480 mg of PF-06473871 or placebo

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01753791 - Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults | Biotech Hunter | Biotech Hunter